Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
IMU Biosciences logo — Decoding the immune system to transform how we understand, d...

IMU Biosciences

Decoding the immune system to transform how we understand, diagnose and treat disease. We call this HD Immunology.

Founded 2019 United Kingdom London, United Kingdom 80 employees Series A Total: $11.50M Biotechnology, Health Care +1

General Information

Company Name IMU Biosciences
Founded Year 2019
Location United Kingdom London, United Kingdom
Employees 80
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with IMU Biosciences. To contact IMU Biosciences, visit imubiosciences.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does IMU Biosciences compare?

A PDF of IMU Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting IMU Biosciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About IMU Biosciences

IMU Biosciences is a biotechnology startup based in the United Kingdom, founded in 2019. The company's slogan "Mapping the immune system across health and disease to power precision medicine" encapsulates its core mission. IMU Biosciences is dedicated to mapping the immune system in unprecedented detail and scale, using a discovery platform that leverages next-generation high-resolution, systems-level immune profiling with AI & ML analytics.

Notably, IMU Biosciences secured a significant milestone with their £11.50M Series A investment on 24 January 2024. The investment was led by Molten Ventures and Life Extension Ventures, showcasing the confidence these industry players have in the potential impact of IMU's innovative approach.

With its focus on precision medicine and leveraging advanced technologies, IMU Biosciences stands at the forefront of revolutionizing treatments and understandings of various health conditions. This recent investment is poised to propel the company forward in advancing its pioneering work in immune system mapping and analysis.

Business keywords: immunology, precision medicine, AI/ML analytics, immune profiling, digital health

Services & Products

Systems-level immune insights and tools for precision medicine development

Target Customers

Biopharmaceutical companies research organizations academic institutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A £11.50M 2
Molten Ventures Life Extension Ventures
Molten Ventures, Life Extension Ventures
24 Jan 2024
Venture Round Undisclosed 1
Beaumont Capital
01 Jan 2023

Latest News

View All
Molten Ventures raises €203 million to back UK and European growth-stage tech companies — Eu-startups
Molten Ventures raises €203 million to back UK and European growth-stage tech companies
Eu-startups Sep 07, 2026

IMU Biosciences Alternatives & Competitors

View All Alternatives
IMU Biosciences vs
DxTerity
DxTerity United States

Bringing the power of precision medicine to autoimmune disease

Venture round
31 employees
Biotechnology, Health Care
Compare IMU Biosciences vs DxTerity
IMU Biosciences vs
Adaptive Biotechnologies Corp.
Adaptive Biotechnologies Corp. United States

Every immune system has a story to tell; the key is knowing how to listen.

IPO
654 employees
Biotechnology, Health Care
Compare IMU Biosciences vs Adaptive Biotechnologies Corp.
IMU Biosciences vs
Alumis
Alumis United States

Transforming the lives of patients living with immune-mediated diseases using a precision approach.

Series C
249 employees
Biotechnology, Health Care
View all alternatives

FAQ About IMU Biosciences

Decoding the immune system to transform how we understand, diagnose and treat disease. We call this HD Immunology.
IMU Biosciences was founded in 2019.
IMU Biosciences is headquartered in London, United Kingdom.
IMU Biosciences operates in Biotechnology, Health Care and Life Sciences. Its work centres on immunology, precision medicine, AI/ML analytics and immune profiling. Its customers include Biopharmaceutical companies, research organizations and academic institutions.
IMU Biosciences has approximately 80 employees.
IMU Biosciences has completed 2 funding rounds, raising a total of $11.50M. The latest funding stage is Series A.
IMU Biosciences offers: Systems-level immune insights and tools for precision medicine development.
Top alternatives and competitors to IMU Biosciences include DxTerity, Adaptive Biotechnologies Corp., Alumis, HTG Molecular Diagnostics, Vir Biotechnology, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
IMU Biosciences and DxTerity are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for IMU Biosciences, https://bouncewatch.com/company/imu-biosciences, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout